Bank of Montreal Can Boosts Stake in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bank of Montreal Can grew its holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 15.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 7,127 shares of the company’s stock after purchasing an additional 937 shares during the period. Bank of Montreal Can’s holdings in Prestige Consumer Healthcare were worth $557,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also modified their holdings of the business. MML Investors Services LLC raised its stake in shares of Prestige Consumer Healthcare by 16.5% in the 3rd quarter. MML Investors Services LLC now owns 4,328 shares of the company’s stock valued at $312,000 after acquiring an additional 612 shares during the period. Barclays PLC raised its position in Prestige Consumer Healthcare by 346.3% in the third quarter. Barclays PLC now owns 92,444 shares of the company’s stock valued at $6,665,000 after purchasing an additional 71,730 shares during the period. Franklin Resources Inc. lifted its stake in Prestige Consumer Healthcare by 4.3% during the third quarter. Franklin Resources Inc. now owns 21,585 shares of the company’s stock worth $1,513,000 after purchasing an additional 894 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Prestige Consumer Healthcare by 3.2% during the third quarter. JPMorgan Chase & Co. now owns 272,255 shares of the company’s stock worth $19,630,000 after buying an additional 8,533 shares during the period. Finally, GAMMA Investing LLC grew its stake in shares of Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company’s stock valued at $108,000 after buying an additional 220 shares in the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Prestige Consumer Healthcare Trading Down 2.1 %

PBH opened at $78.62 on Tuesday. The business’s 50-day simple moving average is $84.04 and its 200-day simple moving average is $80.31. The company has a market cap of $3.89 billion, a P/E ratio of 18.41, a PEG ratio of 2.69 and a beta of 0.47. Prestige Consumer Healthcare Inc. has a one year low of $62.35 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68.

Prestige Consumer Healthcare (NYSE:PBH) last issued its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share for the quarter, topping the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities research analysts expect that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the company’s stock in a transaction dated Monday, March 10th. The stock was sold at an average price of $90.00, for a total value of $151,020.00. Following the completion of the sale, the senior vice president now directly owns 17,157 shares of the company’s stock, valued at $1,544,130. This represents a 8.91 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.60% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Tuesday, April 8th. Canaccord Genuity Group upped their price objective on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a “buy” rating in a research report on Friday, February 7th. Royal Bank of Canada lifted their target price on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the company a “sector perform” rating in a report on Friday, March 21st. DA Davidson increased their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a research report on Friday, February 7th. Finally, Oppenheimer boosted their price objective on Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research report on Thursday, February 13th. Four research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $93.33.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.